Clinical Trials Browser

Phase 1 × Interventional × talazoparib × Clear all

NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Phase 1 Recruiting

Neoplasm Metastasis

NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Phase 1 Recruiting

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT04170946 2026-03-05

Talazoparib

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT05101551 2025-05-29

PARPAML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04846478 2025-04-17

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05053854 2025-02-20

PARLuNET

Phase 1 Recruiting

Neuroendocrine Tumors

NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04207190 2024-11-01

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled 43 charts

Breast Neoplasms, Neoplasms

NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05425862 2023-12-11

REPAIR

Phase 1 Suspended

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT04598321 2023-10-12

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Phase 1 Terminated

1 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02317874 2023-08-29

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Phase 1 Completed

Neoplasm Metastasis

NCT03426254 2023-03-29

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms

NCT02049593 2022-09-26

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasm Metastasis

NCT03077607 2021-06-30

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

36 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02997176 2021-02-25

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

Phase 1 Completed

38 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02392793 2021-02-09

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Phase 1 Completed

Other solid neoplasm

Childhood Solid Tumors

NCT02997163 2021-01-05

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

Phase 1 Completed

34 enrolled 39 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Phase 1 Terminated

BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer

NCT03042910 2019-12-17

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

Phase 1 Completed

38 enrolled 24 charts

Other solid neoplasm

Solid Tumor

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT03070548 2018-12-17

A Study of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

6 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02537561 2016-02-11

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung